Ertumaxomab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ertumaxomab
Monoclonal antibody
TypeTrifunctional antibody
SourceRat/mouse hybrid
TargetHER2/neu, CD3
Clinical data
Trade namesRexomun
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 ☒N☑Y (what is this?)  (verify)

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1]

Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[2] (So they could concentrate on their other product catumaxomab (trade name Removab).[3]:35)

References[edit]